Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 92
Filtrar
1.
J Cosmet Dermatol ; 21(2): 679-688, 2022 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-33811776

RESUMO

BACKGROUND: Intertrigo is an inflammatory skin-fold condition. Candida infections may occur concurrently or afterward. Topical corticosteroids may reduce inflammation but exacerbate Candida infections. The treatment is contentious. OBJECTIVE: To evaluate the efficacies and safety of adsorbent lotion containing tapioca starch, spent grain wax, Butyrospermum parkii extract, argania spinosa kernel oil, aloe barbadensis, rosehip oil, and allantoin for the treatment of mild-to-moderate intertrigo, relative to 1% hydrocortisone cream. METHODS: This randomized, double-blinded study enrolled 40 intertrigo patients. Twice daily, 20 patients applied adsorbent lotion while the remainder used 1% hydrocortisone cream. Efficacy evaluation, skin biophysical measurements, skin tolerability, safety, and visual analog scale (VAS) patient-satisfaction scores were evaluated at baseline and Week 2. RESULTS: The adsorbent lotion showed higher complete cure rates for color, partial epidermal loss, papules/pustules/vesicles/patches, dryness, and scaling than the corticosteroid without statistical significance. Adsorbent lotion demonstrated significantly higher reduction in pruritus than the corticosteroid treatment. Reduction of erythema level using Mexameter and VAS patient-satisfaction scores were not statistically different between adsorbent lotion and hydrocortisone cream. No adverse effects or superimposed infections were reported. CONCLUSIONS: The anti-inflammatory efficacies of adsorbent lotion and low-potency steroid were equivalent. The lotion was safe and produced excellent pruritus reduction. Patient satisfaction was high.


Assuntos
Intertrigo , Creme para a Pele , Administração Tópica , Corticosteroides/administração & dosagem , Alantoína , Aloe , Método Duplo-Cego , Humanos , Intertrigo/tratamento farmacológico , Manihot , Extratos Vegetais , Óleos de Plantas , Rosa , Índice de Gravidade de Doença , Creme para a Pele/efeitos adversos , Creme para a Pele/química , Amido , Resultado do Tratamento
2.
J Cosmet Dermatol ; 20 Suppl 1: 23-27, 2021 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-33934472

RESUMO

BACKGROUND: Intertrigo is a recurrent inflammatory dermatosis involving large/small body folds. Skin barrier products represent the mainstay of treatment in uncomplicated mild/moderate intertrigo. AIMS: To assess by clinical and instrumental evaluation the efficacy and tolerability of a new barrier spray containing zinc gluconate-taurine complex and zinc oxide combined with panthenol, glycerin, and Shea (Butyrospermum parkii) butter in mild-to-moderate intertrigo in athletes and overweight subjects. METHODS: In this open-label prospective trial, 20 adult patients, with mild/moderate intertrigo enrolled at the Dermatology University Clinic of Catania (Italy), were instructed to apply the spray twice daily for 30 days. Degree of erythema was performed clinically and by polarized dermoscopy using a 5-point severity scale (from 0=no erythema to 4=severe erythema) at baseline, and at 15 and 30 days. The measurement of pruritus was carried out by a subject-completed visual analog scale (VAS) (from 0 mm=no pruritus to 100 mm=severe pruritus), at all time points. An Investigator Global Assessment (IGA) using a 6-point scale (from -1=worsening to 4=complete response/clear) was also conducted at 30 days, along with a self-administered tolerability questionnaire. Statistical analysis was performed using SAS version 9. RESULTS: At 15 days, a statically significant reduction from baseline in erythema severity (mean from 3.4 ± 0.3 to 2.5 ± 0.2) along with pruritus intensity (mean from 70 ± 15.4 mm to 40 ± 9.5 mm) was observed. At 30 days, all evaluated parameters showed a further progressive statistically significant reduction from baseline. No relevant side effects were recorded. CONCLUSIONS: Our results suggest that the tested spay containing antiseptic/anti-inflammatory and anti-irritation agents may represent a valid therapeutic option for mild/moderate intertrigo.


Assuntos
Intertrigo , Adulto , Anti-Inflamatórios/uso terapêutico , Atletas , Humanos , Intertrigo/tratamento farmacológico , Sobrepeso , Estudos Prospectivos , Resultado do Tratamento
4.
PLoS One ; 15(8): e0235689, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32760092

RESUMO

Intertrigo is a skin fold dermatitis often requiring recurrent treatment with topical antiseptics or antibiotics, which can select antimicrobial resistance. To minimize this risk, we tested the effectiveness of medical-grade Manuka honey at treating intertrigo as compared to a placebo hydrogel. We additionally characterized the culturable microbial flora of intertrigo and recorded any adverse effect with either treatment. During this randomized, placebo-controlled, double-blinded, adaptive group-sequential trial, the owners washed the affected sites on their dog with water, dried and applied a thin film of either the honey or the placebo product once daily for 21 days. Cytological and lesional composite scores, owner-assessed pruritus, and microbial cultures were assessed prior to treatment and on Day-22. The fixed effects of time, treatment, and animal-related variables on the pruritus and on each composite score, accounting for random dog effect, were estimated separately with generalized linear mixed models for repeated count outcomes (α = 0.05). The null hypothesis of equal treatment effects was rejected at the first interim analysis. The placebo (n = 16 dogs) outperformed the medical honey (n = 13 dogs) at improving both the cytological score (Treatment×Time = -0.35±0.17; P = 0.04) and clinical score (Treatment×Time = -0.28±0.13; P = 0.04). A microbial burden score higher than 4 increased the severity of the cytological score (dichotomous score: 0.29±0.11; P = 0.01), which in turn increased the severity of the clinical score and pruritus score. For every unit increase in cytological score, the linear predictor of clinical score increased by 0.042±0.019 (P = 0.03), and the one of pruritus score increased by 0.12±0.05 (P = 0.01). However, medical honey outperformed the placebo at alleviating the dog's owner-assessed pruritus after statistically controlling for masking effects (Time = -0.94±0.24; P = 0.002; and Treatment×Time = 0.80±0.36; P = 0.04). Unilateral tests of the least-square mean estimates revealed that honey only significantly improved the pruritus (Hommel-adjusted P = 0.003), while the placebo only improved the cytological and clinical scores (Hommel-adjusted P = 0.01 and 0.002, respectively). Taken together, these results question the value of Manuka honey at treating nasal intertrigo in dogs.


Assuntos
Apiterapia , Doenças do Cão , Mel , Intertrigo , Prurido , Animais , Cães , Feminino , Masculino , Apiterapia/métodos , Doenças do Cão/diagnóstico , Doenças do Cão/etiologia , Doenças do Cão/terapia , Método Duplo-Cego , Hidrogéis/administração & dosagem , Intertrigo/complicações , Intertrigo/tratamento farmacológico , Intertrigo/veterinária , Nariz , Placebos/administração & dosagem , Prurido/diagnóstico , Prurido/tratamento farmacológico , Prurido/etiologia , Prurido/veterinária
6.
BMJ Case Rep ; 12(8)2019 Aug 02.
Artigo em Inglês | MEDLINE | ID: mdl-31377719

RESUMO

Systemic drug exposure can produce a skin reaction consisting of symmetrical erythema involving the gluteal and intertriginous areas in the absence of systemic involvement. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) occurs after systemic exposure to a drug in which the patient was not previously sensitised, either in the first dose or after several doses. The mechanism of SDRIFE is unknown but is hypothesised to be the result of a delayed hypersensitivity response resulting in a cutaneous eruption some days after the exposure to the drug. The diagnosis should be clinical, based on the history and examination, but skin tests can also be performed to confirm sensitisation. But, as always, the gold-standard test is oral provocation. It is important to know this clinical entity to prevent re-exposure to the responsible allergen in the future.


Assuntos
Clindamicina/efeitos adversos , Toxidermias/diagnóstico , Exantema/induzido quimicamente , Intertrigo/induzido quimicamente , Administração Oral , Biópsia , Toxidermias/tratamento farmacológico , Toxidermias/patologia , Exantema/tratamento farmacológico , Exantema/patologia , Feminino , Humanos , Intertrigo/tratamento farmacológico , Intertrigo/patologia , Pessoa de Meia-Idade , Esteroides/administração & dosagem , Esteroides/uso terapêutico , Resultado do Tratamento
8.
J Dermatol ; 46(6): 535-539, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31021010

RESUMO

Pegylated liposomal doxorubicin (PLD) is an anthracycline anticancer agent used in ovarian cancer and a form of doxorubicin enclosed in pegylated liposomes. There are only a few reports on intertrigo-like eruptions caused by PLD. We describe the first case of severe bullous erythema, including intertrigo-like eruptions with angioedema, induced by PLD in Japan. We present the case of a 53-year-old woman who was diagnosed with stage IIIC ovarian cancer. After receiving three cycles of PLD, the patient developed swelling of the upper lip and painful erythema with blisters and erosions on the axilla, upper back, flank and wrists. The patient was diagnosed with angioedema and severe skin lesions, including intertrigo-like eruptions induced by PLD. Although treatment with oral prednisolone and topical steroids was effective against these eruptions, the administration of PLD was discontinued because of its ineffectiveness against the primary disease. Several risk factors, such as obesity, perspiration and racial differences, may contribute toward a severe manifestation such as that seen in our patient. Moreover, our case was the first accompanied by angioedema. The mechanism of coexistence of intertrigo-like eruptions and angioedema is not clear; further studies are required to clarify the pathological mechanism of intertrigo-like eruptions.


Assuntos
Antibióticos Antineoplásicos/efeitos adversos , Doxorrubicina/análogos & derivados , Toxidermias/etiologia , Prednisolona/administração & dosagem , Administração Oral , Angioedema/induzido quimicamente , Angioedema/diagnóstico , Angioedema/tratamento farmacológico , Angioedema/patologia , Vesícula/induzido quimicamente , Vesícula/diagnóstico , Vesícula/tratamento farmacológico , Vesícula/patologia , Doxorrubicina/efeitos adversos , Toxidermias/diagnóstico , Toxidermias/tratamento farmacológico , Toxidermias/patologia , Eritema/induzido quimicamente , Eritema/diagnóstico , Eritema/tratamento farmacológico , Eritema/patologia , Feminino , Humanos , Intertrigo/induzido quimicamente , Intertrigo/diagnóstico , Intertrigo/tratamento farmacológico , Intertrigo/patologia , Pessoa de Meia-Idade , Neoplasias Ovarianas/tratamento farmacológico , Polietilenoglicóis/efeitos adversos , Pele/efeitos dos fármacos , Pele/patologia , Resultado do Tratamento
11.
Indian J Pharmacol ; 49(1): 119-120, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28458435

RESUMO

Acute generalized exanthematous pustulosis (AGEP) is an uncommon and self-limiting skin rash commonly caused by drugs and is characterized by the acute onset of fever, pustulosis, and neutrophilia from 4 to 10 days after the drug intake. We describe a case of AGEP in a 61-year-old woman that was hospitalized for the acute onset of fever, erythroderma, and pustulosis. Clinical history revealed that she had been treating a bacterial inguinal intertrigo for 4 days with ciprofloxacin 500 mg tablets twice daily and desloratadine 5 mg tablet once daily. To the best of our knowledge, this is the third reported case of AGEP caused by ciprofloxacin, supporting two other previous reports.


Assuntos
Pustulose Exantematosa Aguda Generalizada/etiologia , Antibacterianos/efeitos adversos , Ciprofloxacina/efeitos adversos , Toxidermias/etiologia , Pustulose Exantematosa Aguda Generalizada/patologia , Antibacterianos/administração & dosagem , Ciprofloxacina/administração & dosagem , Toxidermias/patologia , Feminino , Febre/etiologia , Humanos , Intertrigo/tratamento farmacológico , Loratadina/administração & dosagem , Loratadina/análogos & derivados , Pessoa de Meia-Idade
12.
13.
Antimicrob Agents Chemother ; 60(12): 7290-7294, 2016 12.
Artigo em Inglês | MEDLINE | ID: mdl-27671065

RESUMO

Hematologic patients with superficial skin lesions on admission growing Fusarium spp. are at a high risk for developing invasive fusariosis during neutropenia. We evaluated the impact of primary prophylaxis with a mold-active azole in preventing invasive fusariosis in these patients. Between August 2008 and December 2014, patients with acute leukemia or aplastic anemia and recipients of hematopoietic cell transplants were screened on admission with dermatologic and direct exams and fungal cultures of superficial skin lesions. Until November 2009, no interventions were made. Beginning in December 2009, patients with baseline skin lesions and a direct exam and/or culture suggestive of the presence of Fusarium spp. received prophylaxis with voriconazole or posaconazole. Skin lesions in the extremities (mostly onychomycosis and interdigital intertrigo) were present on admission in 88 of 239 episodes (36.8%); 44 lesions had hyaline septate hyphae identified by direct exam, and cultures from 11 lesions grew Fusarium spp. Antimold prophylaxis was given for 20 episodes (voriconazole for 17 and posaconazole for 3). Invasive fusariosis was diagnosed in 14 episodes (5.8%). Among patients with baseline skin lesions with positive cultures for Fusarium spp., 4 of 5 without antimold prophylaxis developed invasive fusariosis versus 0 of 6 with antimold prophylaxis (P = 0.01; 95% confidence interval for the difference between proportions, 22% to 96%). Primary antifungal prophylaxis with an antimold azole may prevent the occurrence of invasive fusariosis in high-risk hematologic patients with superficial skin lesions on admission growing Fusarium spp.


Assuntos
Antifúngicos/uso terapêutico , Fusariose/tratamento farmacológico , Fusariose/prevenção & controle , Fusarium/efeitos dos fármacos , Triazóis/uso terapêutico , Voriconazol/uso terapêutico , Adolescente , Adulto , Idoso , Anemia Aplástica/microbiologia , Feminino , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Humanos , Hospedeiro Imunocomprometido , Intertrigo/tratamento farmacológico , Leucemia/microbiologia , Masculino , Pessoa de Meia-Idade , Onicomicose/tratamento farmacológico , Estudos Prospectivos , Pele/microbiologia , Adulto Jovem
14.
J Biol Regul Homeost Agents ; 30(2 Suppl 3): 89-93, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27498664

RESUMO

Candidal intertrigo is an infection of the skin caused by Candida albicans that typically occurs in opposing cutaneous or muco-cutaneous surfaces. Because Candidiasis requires a damaged and moist environment for infection, it typically occurs in areas of friction such as the skin folds of the body. Candidal intertrigo is often difficult to treat and results are often unsatisfactory. In addition, there is a lack of evidence-based literature supporting prevention and treatments for candidal intertrigo. The aim of the study was to evaluate the efficacy of Dr Michaels® (also branded as Fungatinex®) products in the treatment of fungal intertrigo, in 20 women and 2 men with a mean age of 72. Five patients (3 female and 2 male) had type 2 diabetes and 16 (14 female and 2 male) were obese. The patients were treated with Dr Michaels® (Fungatinex®) moisturising bar, topical ointment (twice daily application) and oral herbal formulation, PSC 200 two tablets twice daily with food. After 2 weeks of treatment, the lesions had mostly resolved in all patients with only slight erythema evident. After six weeks of treatment using the moisturising bar, topical ointment and oral herbal formulations from the Dr Michaels® (Fungatinex®) product family, the lesions had totally resolved in 18 patients, while 4 patients had to continue the therapeutic protocol for another 2 weeks. Our results demonstrate that the Dr Michaels® (Fungatinex®) complementary product family is efficacious in the treatment of recalcitrant candidal intertrigo. Furthermore, this study highlights that the Dr Michaels® (Fungatinex®) product family is fast-acting and well tolerated with no serious adverse events reported. These data have important implications for resistant cases of candidal intertrigo where traditional therapies have failed.


Assuntos
Candidíase Cutânea/tratamento farmacológico , Intertrigo/tratamento farmacológico , Pomadas/uso terapêutico , Fitoterapia , Administração Cutânea , Idoso , Candidíase Cutânea/complicações , Candidíase Cutânea/patologia , Terapias Complementares/métodos , Diabetes Mellitus Tipo 2/complicações , Feminino , Humanos , Intertrigo/complicações , Intertrigo/patologia , Masculino , Obesidade/complicações , Pomadas/administração & dosagem , Pele/efeitos dos fármacos , Pele/patologia , Higiene da Pele/métodos
16.
Clin Dermatol ; 33(4): 456-61, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26051061

RESUMO

Psoriasis is a chronic skin disorder affecting approximately 2% of the European and American population. The most common form of psoriasis is the chronic plaque type. Inverse psoriasis, also named flexural or intertriginous psoriasis, is not considered a separate disease entity but rather a special site of involvement of plaque psoriasis, characterized by its localization to inverse/intertriginous/flexural body sites. We review current evidence and establish whether inverse psoriasis is a separate disease entity based on characteristics in terms of epidemiology, pathogenesis, clinical and histologic presentation, microbiology, and treatment.


Assuntos
Imunossupressores/uso terapêutico , Intertrigo/patologia , Psoríase/classificação , Psoríase/patologia , Qualidade de Vida , Biópsia por Agulha , Medicina Baseada em Evidências , Feminino , Humanos , Imuno-Histoquímica , Intertrigo/tratamento farmacológico , Intertrigo/epidemiologia , Masculino , Prevalência , Estudos Prospectivos , Psoríase/tratamento farmacológico , Ensaios Clínicos Controlados Aleatórios como Assunto , Medição de Risco , Índice de Gravidade de Doença , Tacrolimo/uso terapêutico , Resultado do Tratamento
17.
Clin Dermatol ; 33(4): 471-6, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26051064

RESUMO

Pemphigus vegetans (P Veg), the rarest form of pemphigus, is thought to be a variant of pemphigus vulgaris (PV). Classically, two subtypes of P Veg are recognized: (1) Neumann P Veg, which usually begins as PV with vesicles and bullae that rupture to form hypertrophic granulating erosions, then evolving into vegetating exuding masses; (2) Hallopeau P Veg, initially characterized by pustular lesions that, after rupturing, merge and gradually evolve into vegetating erosions with a centrifugal expansion. The disease typically affects the big folds (axillary, inframammary, inguinocrural, intergluteal), where semiocclusion, maceration, and mixed infections continuously incite exudation and granulation tissue formation (wet P Veg). In nonintertriginous locations, the vegetating buttons can dry out to change into warty, fissured, painful, seborrheic keratosis-like lesions (dry P Veg). Histologic examination indicates hyperplastic epidermis with intramalpighian leukocyte microabscesses and indistinct traits of suprabasal acantholysis. Immunofluorescence findings are similar to those of PV. Diagnosis is straightforward when PV lesions coexist. Difficulties can arise in cases with nonflexural location. Cytology (Tzanck test), histology, immunofluorescence, and ELISA search for anti-desmoglein antibodies are the diagnostic laboratory tools. Systemic treatment is similar to that for PV, high-dose steroids being the first choice therapy. Immunosuppressive agents and etretinate may allow a steroid-sparing effect. Topical treatment is aimed at countering the granulation tissue formation by means of several strategies (sublesional steroid injection, application of medicated gauzes in the involved flexures, chemical cautery or surgical excision of vegetating lesions).


Assuntos
Doença de Darier/patologia , Imunossupressores/uso terapêutico , Intertrigo/patologia , Pênfigo/patologia , Biópsia por Agulha , Doença de Darier/diagnóstico , Diagnóstico Diferencial , Feminino , Imunofluorescência , Humanos , Imuno-Histoquímica , Intertrigo/tratamento farmacológico , Intertrigo/epidemiologia , Masculino , Pênfigo/classificação , Pênfigo/tratamento farmacológico , Pênfigo/epidemiologia , Prevalência , Prognóstico , Medição de Risco , Índice de Gravidade de Doença
18.
Clin Dermatol ; 33(4): 477-82, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26051065

RESUMO

Diaper (napkin) dermatitis is an acutely presenting inflammatory irritant contact dermatitis of the diaper region. It is one of the most common dermatologic diseases in infants and children. In the past, the disease was thought to be caused by ammonia; however, a number of factors, such as friction, wetness, inappropriate skin care, microorganisms, antibiotics, and nutritional defects, are important. Diaper dermatitis commonly affects the lower parts of the abdomen, thighs, and diaper area. Involvement of skin fold regions is typical with diaper dermatitis. At the early stages of the disease, only dryness is observed in the affected area. At later stages, erythematous maceration and edema can be seen. Secondary candidal and bacterial infections can complicate the dermatitis. In the differential diagnosis of the disease, allergic contact dermatitis, intertrigo, psoriasis, atopic and seborrheic dermatitis, and the other diseases should be considered. Causes of the disease should be determined and eliminated primarily. Families need to be informed about the importance of a clean, dry diaper area and the frequency of diaper changes. The use of superabsorbent disposable diapers has decreased the incidence of the disease. Soap and alcohol-containing products should be avoided in cleaning the area. In some cases, corticosteroids and antifungal agents can be administered. If necessary, antibacterial agents and calcineurin inhibitors can also be beneficial.


Assuntos
Dermatite Alérgica de Contato/patologia , Fármacos Dermatológicos/uso terapêutico , Dermatite das Fraldas/tratamento farmacológico , Dermatite das Fraldas/patologia , Intertrigo/patologia , Administração Tópica , Antibacterianos/uso terapêutico , Biópsia por Agulha , Dermatite Alérgica de Contato/diagnóstico , Dermatite Alérgica de Contato/tratamento farmacológico , Diagnóstico Diferencial , Dermatite das Fraldas/diagnóstico , Feminino , Seguimentos , Humanos , Imuno-Histoquímica , Incidência , Lactente , Recém-Nascido , Intertrigo/tratamento farmacológico , Intertrigo/epidemiologia , Masculino , Fatores de Risco , Índice de Gravidade de Doença , Resultado do Tratamento
19.
Clin Dermatol ; 33(4): 437-47, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26051058

RESUMO

Superficial fungal infections are widespread, regardless of age and gender, in populations all around the world and may affect the skin and skin appendages. Although there are thousands of fungal infections from various genera and families in nature, those that are pathogenic for humans and nesting in skin folds are limited in number. The prevalence and distribution of these fungi vary according to the patients and certain environmental factors. Because the areas including the lids, external auditory canal, behind the ears, navel, inguinal region, and axillae, also called flexures, are underventilated and moist areas exposed to friction, they are especially sensitive to fungal infections. Fungi can both directly invade the skin, leading to infections, and indirectly stimulate immune mechanisms due to tissue interaction and their antigenic character and contribute to the development or exacerbation of secondary bacterial infections, seborrheic dermatitis, atopic dermatitis, and psoriasis. Superficial fungal infections can be classified and studied as dermatophyte infections, candidal infections, Malassezia infections, and other superficial infections independently from the involved skin fold areas.


Assuntos
Antifúngicos/uso terapêutico , Dermatomicoses/diagnóstico , Intertrigo/diagnóstico , Intertrigo/tratamento farmacológico , Arthrodermataceae/isolamento & purificação , Dermatite Atópica/diagnóstico , Dermatite Atópica/tratamento farmacológico , Dermatite Atópica/epidemiologia , Dermatite Seborreica/diagnóstico , Dermatite Seborreica/tratamento farmacológico , Dermatite Seborreica/epidemiologia , Dermatomicoses/tratamento farmacológico , Dermatomicoses/epidemiologia , Feminino , Humanos , Intertrigo/epidemiologia , Masculino , Prevalência , Prognóstico , Psoríase/diagnóstico , Psoríase/tratamento farmacológico , Psoríase/epidemiologia , Medição de Risco , Índice de Gravidade de Doença , Tinha/diagnóstico , Tinha/tratamento farmacológico , Tinha/epidemiologia , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...